Fig. 1From: Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALLRepresentative flow cytometric analysis of a Ph+ALL patient sample sorted according to the distribution of CD34, CD38 and CD58 expression. In the viable bone marrow mononuclear cells (BMMNCs) of a de novo Ph+ALL patient, the LPCs (CD34+CD38−CD58−) and other cells (CD34+CD38−CD58+, CD34+CD38+CD58− and CD34+CD38+CD58+) fractions were sorted simultaneouslyBack to article page